Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Long-Term Debt of $1.99 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $1.99B | +0.1% |
| 2024 | $1.98B | +0.1% |
| 2023 | $1.98B | +0.1% |
| 2022 | $1.98B | +0.1% |
| 2021 | $1.98B | +0.1% |
| 2020 | $1.98B | — |
| 2019 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.99B | +0.1% | +0.0% |
| June 30, 2025 | $1.99B | +0.1% | +0.0% |
| March 31, 2025 | $1.98B | +0.1% | +0.0% |
| December 31, 2024 | $1.98B | +0.1% | +0.0% |
| September 30, 2024 | $1.98B | +0.1% | +0.0% |
| June 30, 2024 | $1.98B | +0.1% | +0.0% |
| March 31, 2024 | $1.98B | +0.1% | +0.0% |
| December 31, 2023 | $1.98B | +0.1% | +0.0% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +0.1% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: